All In Biotech

Drug Trial Radar · NCT07332533

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

A Phase II/III Study of KN026 Combined Chemotherapy With or Without Enlonstobart as First-line Treatment in HER2-positive Unresectable Locally Advanced or Metastatic Gastric Cancer.

Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

490

Planned (sponsor's estimate)

Start

Dec 30, 2025

Primary completion

Jun 30, 2032

Study completion Dec 31, 2032

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Jan 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.

Conditions

  • HER2-positive Gastric Cancer

Interventions

  • KN026Drug

    In accordance with the protocol

  • CapecitabineDrug

    Capecitabine is for oral administration.

  • EnlonstobartDrug

    Enlonstobart is administered by intravenous infusion.

  • OxaliplatinDrug

    Oxaliplatin is administered by intravenous infusion.

  • TrastuzumabDrug

    Trastuzumab is administered by intravenous infusion.

  • PembolizumabDrug

    Pembolizumab is administered by intravenous infusion.

  • CisplatinDrug

    Cisplatin is administered by intravenous infusion.

  • FluorouracilDrug

    Fluorouracil is administered by intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) by investigator in Phase IITime frame: Up to approximately 5 years
  2. Progression-Free Survival (PFS) by BIRC in Phase IIITime frame: Up to approximately 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.